Dissolution behavior of ZnO nanoparticles at environmentally relevant low concentrations in surface waters: Equilibrium and kinetics.

Environmentally relevant fate parameters are essential in accurate prediction of nanomaterial's exposure. This study investigates the dissolution kinetics and equilibrium of ZnO nanoparticles (ZnONPs) using environmentally relevant low concentrations (50-200 µg/L) of ZnONPs in river water and lake water samples, and a seawater-influenced river water. We found that ZnONPs at an initial concentration of 50 µg/L completely dissolved independent of water matrices, while at 100 and 200 µg/L the dissolution level of ZnONPs was strongly dependent on the water chemistry. Carbonate alkalinity was found to control the dissolution levels, and can react with dissolved Zn ion to form secondary solid product hydrozincite. An analysis of our kinetic data and comprehensive literature results reveals that the dissolution kinetic coefficients largely increased with decreased initial ZnONP concentrations especially in environmental water matrices. The result highlights the importance to measure and derive representative dissolution parameters of nanomaterials using environmentally relevant concentrations.

A two-dimensional nanoparticle characterization method combining differential mobility analyzer and single-particle inductively coupled plasma-mass spectrometry with an atomizer-enabled sample introduction (ATM-DMA-spICP-MS): Toward the analysis of heteroaggregated nanoparticles in wastewater.

Characterizing engineered nanoparticles (ENPs) in complex environmental matrices remains a challenging task. This work presents a two-dimensional size analysis method by combining differential mobility analyzer (DMA) and single-particle inductively coupled plasma-mass spectrometry (spICP-MS) with a new atomizer (ATM)-enabled sample introduction that is relatively easy to operate. The tailing of electrical mobility size distributions was solved by heating the aerosol flow, where water-shelled gold nanoparticles (AuNPs) were dehydrated, effectively eliminating the tailing. The improved method has a good sizing performance and can resolve the size fractions of mixed 30 nm and 50 nm AuNPs. It can reliably analyze 7.8 × 105 to 1.9 × 107 # of 50 nm AuNPs (or 4.1 × 105 to 107 # NPs/mL, equivalent to 0.6 to 14.3 µg Au/L) with a linear response and a limit of detection of 7.8 × 105 # AuNPs (equivalent to 4.1 × 105 # AuNPs/mL) that is relevant to NP concentrations in surface water and wastewater samples. The potential of this method to analyze environmental samples was demonstrated by characterizing AuNPs and silver nanoparticles (AgNPs) spiked in wastewater, where both NPs were revealed to form heteroaggregates with colloids existing in wastewater. The method can even directly analyze nanosized Ag particles inherent in the wastewater before adding external AgNPs. The result indicates that ATM-DMA-spICP-MS is a relatively simple two-dimensional size analysis method that has a great potential to characterize heteroaggregated NPs in aqueous environmental samples.

A Review on the Environmental Fate Models for Predicting the Distribution of Engineered Nanomaterials in Surface Waters.

Exposure assessment is a key component in the risk assessment of engineered nanomaterials (ENMs). While direct and quantitative measurements of ENMs in complex environmental matrices remain challenging, environmental fate models (EFMs) can be used alternatively for estimating ENMs' distributions in the environment. This review describes and assesses the development and capability of EFMs, focusing on surface waters. Our review finds that current engineered nanomaterial (ENM) exposure models can be largely classified into three types: material flow analysis models (MFAMs), multimedia compartmental models (MCMs), and spatial river/watershed models (SRWMs). MFAMs, which is already used to derive predicted environmental concentrations (PECs), can be used to estimate the releases of ENMs as inputs to EFMs. Both MCMs and SRWMs belong to EFMs. MCMs are spatially and/or temporally averaged models, which describe ENM fate processes as intermedia transfer of well-mixed environmental compartments. SRWMs are spatiotemporally resolved models, which consider the variability in watershed and/or stream hydrology, morphology, and sediment transport of river networks. As the foundation of EFMs, we also review the existing and emerging ENM fate processes and their inclusion in recent EFMs. We find that while ENM fate processes, such as heteroaggregation and dissolution, are commonly included in current EFMs, few models consider photoreaction and sulfidation, evaluation of the relative importance of fate processes, and the fate of weathered/transformed ENMs. We conclude the review by identifying the opportunities and challenges in using EFMs for ENMs.

Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers.

BACKGROUND: Enterovirus 71 (EV71) has caused several epidemics of hand, foot and mouth diseases (HFMD) in Asia. No effective EV71 vaccine is available. A randomized and open-label phase I clinical study registered with ClinicalTrials.gov #NCT01268787, aims to evaluate the safety, reactogenicity and immunogenicity of a formalin-inactivated EV71 vaccine candidate (EV71vac) at 5- and 10-µg doses. In this study we report the cross-neutralizing antibody responses from each volunteer against different subgenotypes of EV71 and CVA16. METHODS: Sixty eligible healthy adults were recruited and vaccinated. Blood samples were obtained on day 0, 21 and 42 and tested against B1, B4, B5, C2, C4A, C4B and CVA16 for cross-neutralizing antibody responses. RESULTS: The immunogenicity of both 5- and 10- µg doses were found to be very similar. Approximately 45% of the participants had <8 pre-vaccination neutralization titers (Nt) against the B4 vaccine strain. After the first EV71vac immunization, 95% of vaccinees have >4-fold increase in Nt, but there was no further increase in Nt after the second dose. EV71vac induced very strong cross-neutralizing antibody responses in >85% of volunteers without pre-existing Nt against subgenotype B1, B5 and C4A. EV71vac elicited weak cross-neutralizing antibody responses (∼20% of participants) against a C4B and Coxsackie virus A16. Over 90% of vaccinated volunteers did not develop cross-neutralizing antibody responses (Nt<8) against a C2 strain. EV71vac can boost and significantly enhance the neutralizing antibody responses in volunteers who already had pre-vaccination antibodies against EV71 and/or CVA16. CONCLUSION: EV71vac is efficient in eliciting cross-neutralizing antibody responses against EV71 subgenotypes B1, B4, B5, and C4A, and provides the rationale for its evaluation in phase II clinical trials. TRIAL REGISTRATION: ClinicalTrials.gov NCT01268787.

A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine.

BACKGROUND: Large-scale outbreaks of enterovirus 71 (EV71) infections have occurred in Asia-Pacific regions. Severe complications include encephalitis and poliomyelitis-like paralysis, cardiopulmonary collapse, and death, necessitating an effective vaccine against EV71. METHODS: In this randomized Phase I study, we evaluated the safety and immunogenicity of an inactivated alum-adjuvanted EV71 whole-virus vaccine produced on Vero cell cultures. Sixty healthy volunteers aged 20-60 years received two doses of vaccine, administered 21 days apart. Each dose contained either 5 µg of EV71 antigen with 150 µg of adjuvant (Group A05) or 10 µg of EV71 antigen with 300 µg of adjuvant (Group B10). Serologic analysis was performed at baseline, day 21, and day 42. RESULTS: There were no serious adverse events. Mild injection site pain and myalgia were the most common adverse events with either vaccine formulation. The immunogenicity data showed that 90% of vaccine recipients have a 4-fold or greater increase in neutralization antibody titers (NT) after the first dose, without a further increase in NT after the second dose. The seroconversion rates on day 21 and day 42 were 86.7% and 93.1% respectively, in Group A05, and 92.9% and 96.3%, respectively, in Group B10. Thus, 5 µg and 10 µg of the EV71 vaccine can induce a remarkable immune response in healthy adults after only the first vaccination. CONCLUSION: The 5 µg and 10 µg adjuvanted EV71 vaccines are generally safe and immunogenic in healthy adults. (ClinicalTrials.gov number, NCT01268787).